Using colon adenocarcinoma (MC38) and mammary (EMT6) mouse models, this study revealed that therapeutic blockade of TGF-β with antibodies promoted CD8+ T-cell inflammation and anti-tumor immunity, sensitizing tumors to PD-L1 therapy [113]. This evidence concerns the gene CD8A and neoplasm.